Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone and Imatinib in Chronic Phase CML
NCT02687425Phase 2Unknown
- Start
- Feb 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of pioglitazone in Chronic Myeloid Leukemia (CML). Primary endpoint: Complete Molecular Response rate at 1 year. Status: unknown.
02
Drugs
pioglitazone
03
Conditions
Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT02687425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02687425.